New developments in the management of vulvovaginal atrophy: a comprehensive overview

References

• Lev-Sagie A. Vulvar and vaginal atrophy: physiology, clinical presentation, and treatment considerations. Clin Obstet Gynecol. 2015;58(3):476–491.
   PubMed Web of Science ®Google Scholar
• Nappi RE, Martini E, Cucinella L, et al., Addressing Vulvovaginal Atrophy (VVA)/Genitourinary Syndrome of Menopause (GSM) for healthy aging in women. Front Endocrinol (Lausanne). 2019 Aug 21; 10:561. PMID: 31496993; PMCID: PMC6712495
   PubMed Web of Science ®Google Scholar
• Palacios S, Nappi RE, Bruyniks N, et al. The European Vulvovaginal Epidemiological Survey (EVES): prevalence, symptoms and impact of vulvovaginal atrophy of menopause. Climacteric. 2018;21(3):286–291.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Wei J, Yang X, et al. Investigation on prevalence and risk factors associated with genitourinary syndrome of menopause in middle-aged and older women in Beijing community: a cross sectional study. BMC Womens Health. 2022 Dec 30;22(1):558. PMID: 36585649; PMCID: PMC9801667.
   PubMedGoogle Scholar
• Gandhi J, Chen A, Dagur G, et al. Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management. Am J Obstet Gynecol. 2016;215(6):704–711.
   PubMed Web of Science ®Google Scholar
• Donders GGG, Ruban K, Bellen G, et al. Pharmacotherapy for the treatment of vaginal atrophy. Expert Opin Pharmacother. 2019;20(7):821–835.
   PubMed Web of Science ®Google Scholar
• Takashina R, Nakajima T, Umezu T, et al. Stratification of mouse vaginal epithelium 2. Identification of factors inducing stratification. Biol Reprod. 2018;99(4):727–734.
   PubMedGoogle Scholar
• Pessina MA, Hoyt RF Jr., Goldstein I, et al. Differential effects of estradiol, progesterone, and testosterone on vaginal structural integrity. Endocrinology. 2006;147(1):61–69.
   PubMed Web of Science ®Google Scholar
• Berman JR, Almeida FG, Jolin J, et al. Correlation of androgen receptors, aromatase, and 5-alpha reductase in the human vagina with menopausal status. Fertil Steril. 2003;79(4):925–931.
   PubMed Web of Science ®Google Scholar
• Labrie F, Martel C, Pelletier G. Is vulvovaginal atrophy due to a lack of both estrogens and androgens? Menopause. 2017;24(4):452–461.
   PubMed Web of Science ®Google Scholar
• Labrie F. Intracrinology and menopause: the science describing the cell-specific intracellular formation of estrogens and androgens from DHEA and their strictly local action and inactivation in peripheral tissues. Menopause. 2019;26(2):220–224.
   PubMedGoogle Scholar
• Labrie F, Bélanger A, Pelletier G, et al. Science of intracrinology in postmenopausal women. Menopause. 2017;24(6):702–712.
   PubMedGoogle Scholar
• Labrie F, Derogatis L, Archer DF, et al. Effect of intravaginal prasterone on sexual dysfunction in postmenopausal women with vulvovaginal atrophy. J Sex Med. 2015;12(12):2401–2412.
   PubMed Web of Science ®Google Scholar
• Bikle D, Teichert A, Hawker N, et al. Sequential regulation of keratinocyte differentiation by 1,25(OH)2D3, VDR, and its coregulators. J Steroid Biochem Mol Biol. 2007;103(3–5):396–404.
   PubMed Web of Science ®Google Scholar
• Niki E, Traber MG. A history of vitamin E. Ann Nutr Metab. 2012;61(3):207–212.
   PubMed Web of Science ®Google Scholar
• Al-Saqi SH, Jonasson AF, Naessen T, et al. Oxytocin improves cytological and histological profiles of vaginal atrophy in postmenopausal women. Post Reproductive Health. 2016;22(1):25–33.
   PubMedGoogle Scholar
• de Landsheere L, Brieu M, Blacher S, et al. Elastin density: link between histological and biomechanical properties of vaginal tissue in women with pelvic organ prolapse? International Urogynecology Journal. 2016;27(4):629–635.
   PubMedGoogle Scholar
• Kerkhof MH, Ruiz-Zapata AM, Bril H, et al. Changes in tissue composition of the vaginal wall of premenopausal women with prolapse. Am J Obstet Gynecol. 2014;210(2):168 e1–9.
   PubMedGoogle Scholar
• Vetuschi A, D’Alfonso A, Sferra R, et al. Changes in muscularis propria of anterior vaginal wall in women with pelvic organ prolapse. Eur J Histochem. 2016;60(1):2604.
   PubMed Web of Science ®Google Scholar
• Berman JR, McCarthy MM, Kyprianou N. Effect of estrogen withdrawal on nitric oxide synthase expression and apoptosis in the rat vagina. Urology. 1998;51(4):650–656.
   PubMed Web of Science ®Google Scholar
• Min K, Munarriz R, Kim NN, et al. Effects of ovariectomy and estrogen and androgen treatment on sildenafil-mediated changes in female genital blood flow and vaginal lubrication in the animal model. Am J Obstet Gynecol. 2002;187(5):1370–1376.
   PubMedGoogle Scholar
• Palma F, Volpe A, Villa P, et al. Vaginal atrophy of women in postmenopause. Results from a multicentric observational study: the AGATA study. Maturitas 2016;83:40–44.
   PubMed Web of Science ®Google Scholar
• Portman DJ, Gass ML. Vulvovaginal atrophy terminology consensus conference Panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women’s Sexual Health and the North American Menopause Society. Menopause 2014; 21: 1063–1068.
   Google Scholar
• Vieira-Baptista P, Marchitelli C, Haefner HK, et al. Deconstructing the genitourinary syndrome of menopause. Int Urogynecol J. 2017;28(5):675–679.
   PubMed Web of Science ®Google Scholar
• Hill EK, Sandbo S, Abramsohn E, et al. Assessing gynecologic and breast cancer survivors’ sexual health care needs. Cancer. 2011 Jun 15;117(12):2643–2651.
   PubMed Web of Science ®Google Scholar
• SOGC clinical practice guidelines. The detection and management of vaginal atrophy. number 145, May 2004. Int J Gynaecol Obstet. 2005;88(2):222–228.
   PubMed Web of Science ®Google Scholar
• Domoney C, Currie H, Panay N, et al. The CLOSER survey: impact of postmenopausal vaginal discomfort on women and male partners in the UK. Menopause Int. 2013;19(2):69–76.
   PubMedGoogle Scholar
• Farrell Am E. Genitourinary syndrome of menopause. Aust Fam Physician. 2017;46(7):481–484.
   PubMedGoogle Scholar
• Goldstein I, Dicks B, Kim NN, et al. Multidisciplinary overview of vaginal atrophy and associated genitourinary symptoms in postmenopausal women. Sex Med. 2013;1(2):44–53.
   PubMed Web of Science ®Google Scholar
• Kingsberg SA, Wysocki S, Magnus L, et al. Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (Real women’s views of treatment options for menopausal vaginal changes) survey. J Sex Med. 2013;10(7):1790–1799.
   PubMed Web of Science ®Google Scholar
• Mouchamps E, Gaspard U. Inhibition of sexual desire associated with menopause. Revue Medicale de Liege. 1999;54(5):489–494.
   PubMedGoogle Scholar
• Nappi RE, Kingsberg S, Maamari R, et al. The CLOSER (Clarifying Vaginal Atrophy’s Impact On Sex And Relationships) survey: implications of vaginal discomfort in postmenopausal women and in male partners. J Sex Med. 2013;10(9):2232–2241.
   PubMed Web of Science ®Google Scholar
• Nappi RE, Palacios S, Panay N, et al. Vulvar and vaginal atrophy in four European countries: evidence from the European REVIVE Survey. Climacteric. 2016;19(2):188–197.
   PubMed Web of Science ®Google Scholar
• Nappi RE, Palacios S, Bruyniks N, et al. EVES Study investigators. The burden of vulvovaginal atrophy on women’s daily living: implications on quality of life from a face-to-face real-life survey. Menopause. 2019 May;26(5):485–491. PMID: 30422932
   PubMed Web of Science ®Google Scholar
• Bachmann G. Urogenital ageing: an old problem newly recognized. Maturitas. 1995;22(Suppl):S1–s5.
   PubMedGoogle Scholar
• Huang AJ, Gregorich SE, Kuppermann M, et al. Day-to-day impact of vaginal aging questionnaire: a multidimensional measure of the impact of vaginal symptoms on functioning and well-being in postmenopausal women. Menopause. 2015;22(2):144–154.
   PubMed Web of Science ®Google Scholar
• Erekson EA, Yip SO, Wedderburn TS, et al. The vulvovaginal symptoms questionnaire: a questionnaire for measuring vulvovaginal symptoms in postmenopausal women. Menopause. 2013;20(9):973–979.
   PubMedGoogle Scholar
• Wiegel M, Meston C, Rosen R. The female sexual function index (FSFI): cross-validation and development of clinical cutoff scores. J Sex Marital Ther. 2005;31(1):1–20.
   PubMed Web of Science ®Google Scholar
• Kao A, Binik YM, Kapuscinski A, et al. Dyspareunia in postmenopausal women: a critical review. Pain Res Manag. 2008;13(3):243–254.
   PubMed Web of Science ®Google Scholar
• Mitro SD, Harlow SD, Randolph JF, et al. Chronic vulvar pain in a cohort of post-menopausal women: atrophy or Vulvodynia? Women’s Midlife Health. 2016;2:4–13.
   PubMedGoogle Scholar
• Donders GGG, Bellen G, Grinceviciene S, et al. Aerobic vaginitis: no longer a stranger. Res Microbiol. 2017;168(9–10):845–858.
   PubMed Web of Science ®Google Scholar
• Lewis FM. Vulval symptoms after the menopause - Not all atrophy! Post Reprod Health. 2015;21(4):146–150.
   PubMedGoogle Scholar
• Greendale GA, Zibecchi L, Petersen L, et al. Development and validation of a physical examination scale to assess vaginal atrophy and inflammation. Climacteric. 1999;2(3):197–204.
   PubMedGoogle Scholar
• van der Laak JA, Schijf CP, Kerstens HM, et al. Development and validation of a computerized cytomorphometric method to assess the maturation of vaginal epithelial cells. Cytometry. 1999;35(3):196–202.
   PubMedGoogle Scholar
• Tucker KM, Godha K, Mirkin S, et al. Vaginal pH: a simple assessment highly correlated with vaginal morphology and symptoms in postmenopausal women. Menopause. 2018;25(7):762–766.
   PubMed Web of Science ®Google Scholar
• Tuntiviriyapun P, Panyakhamlerd K, Triratanachat S, et al. Newly developed vaginal atrophy symptoms II and vaginal pH: a better correlation in vaginal atrophy? Climacteric. 2015;18(2):246–251.
   PubMed Web of Science ®Google Scholar
• Donders GG. Microscopy of the bacterial flora on fresh vaginal smears. Infect Dis Obstet Gynecol. 1999;7(4):177–179.
   PubMedGoogle Scholar
• Donders GG. Definition and classification of abnormal vaginal flora. Best Pract Res Clin Obstet Gynaecol. 2007;21(3):355–373.
   PubMed Web of Science ®Google Scholar
• Donders GG, Marconi C, Bellen G, et al. Effect of short training on vaginal fluid microscopy (wet mount) learning. J Low Genit Tract Dis. 2015;19(2):165–169.
   PubMed Web of Science ®Google Scholar
• Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the women’s health initiative randomized controlled trial. Jama. 2004;291(14):1701–1712.
   PubMed Web of Science ®Google Scholar
• Oerlemans EFM, Wuyts S, Bellen G, et al. The dwindling microbiota of aerobic vaginitis, an inflammatory state enriched in pathobionts with limited TLR stimulation. Diagnostics (Basel). 2020;10:11.
   Google Scholar
• Donders GG, Ruban K, Bellen G. Selecting anti-microbial treatment of aerobic vaginitis. Curr Infect Dis Rep. 2015;17(5):477.
   PubMedGoogle Scholar
• The NAMS 2020 GSM Position Statement Editorial Panel. The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause. 2020 Sep;27(9):976–992.
   PubMed Web of Science ®Google Scholar
• Elizabeth J, Cathcart-Rake MD, Kathryn J, et al. Vaginal estrogen therapy for the genitourinary symptoms of menopause: caution or reassurance? JNCI. 2022 October;114(10):1315–1316.
   PubMedGoogle Scholar
• Cold S, Cold F, Jensen MB, et al. Systemic or vaginal hormone therapy after early breast cancer: a danish observational cohort study. J Natl Cancer Inst. 2022 Oct 6;114(10):1347–1354. PMID: 35854422; PMCID: PMC9552278.
   PubMedGoogle Scholar
• Glaser RL, Zava DT, Wurtzbacher D. Pilot study: absorption and efficacy of multiple hormones delivered in a single cream applied to the mucous membranes of the labia and vagina. Gynecol Obstet Invest. 2008;66(2):111–118.
   PubMed Web of Science ®Google Scholar
• Biehl C, Plotsker O, Mirkin S. A systematic review of the efficacy and safety of vaginal estrogen products for the treatment of genitourinary syndrome of menopause. Menopause. 2019;26(4):431–453.
   PubMed Web of Science ®Google Scholar
• Biglia N. Vaginal atrophy in breast cancer survivors: attitude and approaches among oncologists. Clin Breast Cancer. 2017;8:611–617.
   Google Scholar
• Alvisi S, Baldassarre M, Gava G, et al. Knowledge of genito-urinary syndrome of menopause among Italian gynecologists: the DIADEM survey. Maturitas. 2021 Jan;143:89–95. Epub 2020 Oct 2. PMID: 33308642.
   PubMed Web of Science ®Google Scholar
• Lethaby A, Ayeleke RO, Roberts H. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev. 2016;8:Cd001500.
   PubMed Web of Science ®Google Scholar
• Illston JD, Wheeler TL, Parker CR, et al. Low-dose 17-β-estradiol cream for vaginal atrophy in a cohort without prolapse: serum levels and vaginal response including tissue biomarkers associated with tissue remodeling. Maturitas. 2015;81(4):475–479.
   PubMed Web of Science ®Google Scholar
• Archer DF, Constantine GD, Simon JA, et al. TX-004HR vaginal estradiol has negligible to very low systemic absorption of estradiol. Menopause. 2017;24(5):510–516.
   PubMed Web of Science ®Google Scholar
• Constantine GD, Bouchard C, Pickar JH, et al. Consistency of effect with a low-dose, estradiol vaginal capsule (TX-004HR): evaluating improvement in vaginal physiology and moderate-to-severe dyspareunia in subgroups of postmenopausal women. J Womens Health (Larchmt). 2017;26(6):616–623.
   PubMed Web of Science ®Google Scholar
• Ilhan G, Aslan MM, Cevrioglu AS, et al. Clinical efficacy of hormonal and nonhormonal agents in the treatment of vulvovaginal atrophy. J Menopausal Med. 2021;27(1):15–23.
   PubMedGoogle Scholar
• Del Pup L, Di Francia R, Cavaliere C, et al. Promestriene, a specific topic estrogen. Review of 40 years of vaginal atrophy treatment: is it safe even in cancer patients? Anticancer Drugs. 2013;24(10):989–998.
   PubMed Web of Science ®Google Scholar
• Palacios S, Ramirez M, Lilue M. Efficacy of low-dose vaginal 17β-estradiol versus vaginal promestriene for vulvovaginal atrophy. Climacteric. 2022;25(4):383–387.
   PubMedGoogle Scholar
• Del Pup L, Postruznik D, Corona G. Effect of one-month treatment with vaginal promestriene on serum estrone sulfate levels in cancer patients: a pilot study. Maturitas. 2012;72(1):93–94.
   PubMed Web of Science ®Google Scholar
• Aylward M, Holly F, Parker RJ. An evaluation of clinical response to piperazine oestrone sulphate (‘Harmogen’) in menopause patients. Curr Med Res Opin. 1974;2(7):417–423.
   PubMed Web of Science ®Google Scholar
• Heimer GM, Englund DE. Plasma oestriol following vaginal administration: morning versus evening insertion and influence of food. Maturitas. 1986;8(3):239–243.
   PubMed Web of Science ®Google Scholar
• Bergink EW. Oestriol receptor interactions: their biological importance and therapeutic implications. Acta Endocrinologica Supplementum. 1980;233:9–16.
   PubMedGoogle Scholar
• Birkhauser M. [Prevention of osteoporosis by estrogens]. Revue medicale de la Suisse romande. 1995;115(2):113–120.
   PubMedGoogle Scholar
• van der Vies J. The pharmacology of oestriol. Maturitas. 1982;4(4):291–299.
   PubMedGoogle Scholar
• Griesser H, Skonietzki S, Fischer T, et al. Low dose estriol pessaries for the treatment of vaginal atrophy: a double-blind placebo-controlled trial investigating the efficacy of pessaries containing 0.2mg and 0.03mg estriol. Maturitas. 2012;71(4):360–368.
   PubMed Web of Science ®Google Scholar
• Head KA. Estriol: safety and efficacy. Alternative Med Rev J Clin Ther. 1998;3(2):101–113.
   PubMedGoogle Scholar
• Sánchez-Rovira P, Hirschberg AL, Gil-Gil M, et al. A phase II prospective, randomized, double-blind, placebo-controlled and multicenter clinical trial to assess the safety of 0.005% estriol vaginal gel in hormone receptor-positive postmenopausal women with early stage breast cancer in treatment with aromatase inhibitor in the adjuvant setting. Oncologist. 2020;25(12):e1846–54.
   PubMed Web of Science ®Google Scholar
• Hirschberg AL, Sánchez-Rovira P, Presa-Lorite J, et al. Efficacy and safety of ultra-low dose 0.005% estriol vaginal gel for the treatment of vulvovaginal atrophy in postmenopausal women with early breast cancer treated with nonsteroidal aromatase inhibitors: a phase II, randomized, double-blind, placebo-controlled trial. Menopause. 2020;27(5):526–534.
   PubMed Web of Science ®Google Scholar
• Caruso S, Cianci S, Vitale SG, et al. Effects of ultralow topical estriol dose on vaginal health and quality of life in postmenopausal women who underwent surgical treatment for pelvic organ prolapse. Menopause. 2017;24(8):900–907.
   PubMedGoogle Scholar
• Unlu C, Donders G. Use of lactobacilli and estriol combination in the treatment of disturbed vaginal ecosystem: a review. J Turk Ger Gynecol Assoc. 2011;12(4):239–246.
   PubMedGoogle Scholar
• Donders GG, Van Bulck B, Van de Walle P, et al. Effect of lyophilized lactobacilli and 0.03 mg estriol (Gynoflor(R)) on vaginitis and vaginosis with disrupted vaginal microflora: a multicenter, randomized, single-blind, active-controlled pilot study. Gynecol Obstet Invest. 2010;70(4):264–272.
   PubMed Web of Science ®Google Scholar
• Ozkinay E, Terek MC, Yayci M, et al. The effectiveness of live lactobacilli in combination with low dose oestriol (Gynoflor) to restore the vaginal flora after treatment of vaginal infections. Bjog. 2005;112(2):234–240.
   PubMed Web of Science ®Google Scholar
• Jaisamrarn U, Triratanachat S, Chaikittisilpa S, et al. Ultra-low-dose estriol and lactobacilli in the local treatment of postmenopausal vaginal atrophy. Climacteric. 2013;16(3):347–355.
   PubMed Web of Science ®Google Scholar
• Kanne B, Jenny J. Local administration of low-dose estriol and vital Lactobacillus acidophilus in postmenopause. Gynakologische Rundschau. 1991;31(1):7–13.
   PubMedGoogle Scholar
• Capobianco G, Wenger JM, Meloni GB, et al. Triple therapy with Lactobacilli acidophili, estriol plus pelvic floor rehabilitation for symptoms of urogenital aging in postmenopausal women. Arch Gynecol Obstet. 2014;289(3):601–608.
   PubMed Web of Science ®Google Scholar
• Donders G, Neven P, Moegele M, et al. Ultra-low-dose estriol and Lactobacillus acidophilus vaginal tablets (Gynoflor(®)) for vaginal atrophy in postmenopausal breast cancer patients on aromatase inhibitors: pharmacokinetic, safety, and efficacy phase I clinical study. Breast Cancer Res Treat. 2014;145(2):371–379.
   PubMed Web of Science ®Google Scholar
• Diller M, Schuler S, Buchholz S, et al. Effects of estriol on growth, gene expression and estrogen response element activation in human breast cancer cell lines. Maturitas. 2014;77(4):336–343.
   PubMed Web of Science ®Google Scholar
• Donders G, Bellen G, Neven P, et al. Effect of ultra-low-dose estriol and lactobacilli vaginal tablets (Gynoflor(R)) on inflammatory and infectious markers of the vaginal ecosystem in postmenopausal women with breast cancer on aromatase inhibitors. Eur J Clin Microbiol Infect Dis. 2015;34(10):2023–2028.
   PubMed Web of Science ®Google Scholar
• Buchholz S, Mogele M, Lintermans A, et al. Vaginal estriol-lactobacilli combination and quality of life in endocrine-treated breast cancer. Climacteric. 2015;18(2):252–259.
   PubMed Web of Science ®Google Scholar
• Dorr MB, Nelson AL, Mayer PR, et al. Plasma estrogen concentrations after oral and vaginal estrogen administration in women with atrophic vaginitis. Fertil Steril. 2010;94(6):2365–2368.
   PubMedGoogle Scholar
• Farrell R. ACOG committee opinion no. 659 summary: the use of vaginal estrogen in women with a history of estrogen-dependent breast cancer. Obstet Gynecol. 2016;127(3):618–619.
   PubMed Web of Science ®Google Scholar
• Freedman M, Kaunitz AM, Reape KZ, et al. Twice-weekly synthetic conjugated estrogens vaginal cream for the treatment of vaginal atrophy. Menopause. 2009 July-August;16(4):735–741.
   PubMedGoogle Scholar
• Alvisi S, Baldassarre M, Martelli V, et al. Effects of ospemifene on vaginal epithelium of post-menopausal women. Gynecol Endocrinol. 2017;33(12):946–950.
   PubMed Web of Science ®Google Scholar
• Bachmann GA, Komi JO. Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study. Menopause. 2010;17(3):480–486.
   PubMed Web of Science ®Google Scholar
• Di Donato V, Schiavi MC, Iacobelli V, et al. Ospemifene for the treatment of vulvar and vaginal atrophy: a meta-analysis of randomized trials. Part II: evaluation of tolerability and safety. Maturitas. 2019;121:93–100.
   PubMed Web of Science ®Google Scholar
• Archer DF, Goldstein SR, Simon JA, et al. Efficacy and safety of ospemifene in postmenopausal women with moderate-to-severe vaginal dryness: a phase 3, randomized, double-blind, placebo-controlled, multicenter trial. Menopause. 2019;26(6):611–621.
   PubMed Web of Science ®Google Scholar
• Pup LD, Sánchez-Borrego R. Ospemifene efficacy and safety data in women with vulvovaginal atrophy. Gynecol Endocrinol. 2020;36(7):569–577.
   PubMedGoogle Scholar
• Kangas L, Harkonen P, Vaananen K, et al. Effects of the selective estrogen receptor modulator ospemifene on bone in rats. Hormone Metab Res. 2014;46(1):27–35.
   PubMed Web of Science ®Google Scholar
• Komi J, Lankinen KS, DeGregorio M, et al. Effects of ospemifene and raloxifene on biochemical markers of bone turnover in postmenopausal women. J Bone Miner Metab. 2006;24(4):314–318.
   PubMed Web of Science ®Google Scholar
• Simon JA, Altomare C, Cort S, et al. Overall safety of ospemifene in postmenopausal women from placebo-controlled phase 2 and 3 trials. J Womens Health (Larchmt). 2018;27(1):14–23.
   PubMed Web of Science ®Google Scholar
• Nordstrom BL, Cai B, De Gregorio F, et al. Incidence of venous thromboembolism among postmenopausal women prescribed ospemifene, selective estrogen receptor modulators for noncancer indications, or untreated vulvar and vaginal atrophy. Menopause. 2020;27(8):864–871.
   PubMed Web of Science ®Google Scholar
• Archer DF, Altomare C, Jiang W, et al. Ospemifene’s effects on lipids and coagulation factors: a post hoc analysis of phase 2 and 3 clinical trial data. Menopause. 2017;24(10):1167–1174.
   PubMed Web of Science ®Google Scholar
• Burich RA, Mehta NR, Wurz GT, et al. Ospemifene and 4-hydroxyospemifene effectively prevent and treat breast cancer in the MTag.Tg transgenic mouse model. Menopause. 2012;19(1):96–103.
   PubMed Web of Science ®Google Scholar
• Taras TL, Wurz GT, DeGregorio MW. In vitro and in vivo biologic effects of Ospemifene (FC-1271a) in breast cancer. J Steroid Biochem Mol Biol. 2001;77(4–5):271–279.
   PubMed Web of Science ®Google Scholar
• Wurz GT, Read KC, Marchisano-Karpman C, et al. Ospemifene inhibits the growth of dimethylbenzanthracene-induced mammary tumors in Sencar mice. J Steroid Biochem Mol Biol. 2005;97(3):230–240.
   PubMed Web of Science ®Google Scholar
• Cai B, Simon J, Villa P, et al. No increase in incidence or risk of recurrence of breast cancer in ospemifene-treated patients with vulvovaginal atrophy (VVA). Maturitas. 2020;142:38–44.
   PubMed Web of Science ®Google Scholar
• Lubián López DML. Management of genitourinary syndrome of menopause in breast cancer survivors: an update. World J Clin Oncol. 2022;13(2):71–100.
   PubMed Web of Science ®Google Scholar
• Indhavivadhana S, Leerasiri P, Rattanachaiyanont M, et al. Vaginal atrophy and sexual dysfunction in current users of systemic postmenopausal hormone therapy. J Med Assoc Thai. 2010;93(6):667–675.
   PubMedGoogle Scholar
• Pinkerton JV, Shifren JL, La Valleur J, et al. Influence of raloxifene on the efficacy of an estradiol-releasing ring for treating vaginal atrophy in postmenopausal women. Menopause (New York, N.Y.). 2003;10(1):45–52.
   PubMed Web of Science ®Google Scholar
• Pinkerton JV, Stanczyk FZ. Clinical effects of selective estrogen receptor modulators on vulvar and vaginal atrophy. Menopause. 2014;21(3):309–319.
   PubMed Web of Science ®Google Scholar
• Gennari L. Lasofoxifene, a new selective estrogen receptor modulator for the treatment of osteoporosis and vaginal atrophy. Expert Opin Pharmacother. 2009;10(13):2209–2220.
   PubMed Web of Science ®Google Scholar
• Visser M, Coelingh Bennink HJT. Clinical applications for estetrol. J Steroid Biochem Mol Biol. 2009;114(1–2):85–89.
   PubMed Web of Science ®Google Scholar
• Coelingh Bennink HJ, Holinka CF, Diczfalusy E. Estetrol review: profile and potential clinical applications. Climacteric. 2008;11(Suppl sup1):47–58.
   PubMedGoogle Scholar
• Schmidt M, Lenhard H, Hoenig A, et al. Tumor suppression, dose-limiting toxicity and wellbeing with the fetal estrogen estetrol in patients with advanced breast cancer. J Cancer Res Clin Oncol. 2021;147(6):1833–1842.
   PubMed Web of Science ®Google Scholar
• Santen RJ, Stuenkel CA, Davis SR, et al. Managing menopausal symptoms and associated clinical issues in breast cancer survivors. J Clin Endocrinol Metab. 2017;102(10):3647–3661.
   PubMed Web of Science ®Google Scholar
• Benoit T, Valera M-C, Fontaine C, et al. Estetrol, a fetal selective estrogen receptor modulator, acts on the vagina of mice through nuclear estrogen receptor α activation. Am J Pathol. 2017;187(11):2499–2507.
   PubMed Web of Science ®Google Scholar
• Coelingh Bennink HJT, Verhoeven C, Zimmerman Y, et al. Pharmacokinetics of the fetal estrogen estetrol in a multiple-rising-dose study in postmenopausal women. Climacteric. 2017;20(3):285–289.
   PubMed Web of Science ®Google Scholar
• Coelingh Bennink HJT, Verhoeven C, Zimmerman Y, et al. Clinical effects of the fetal estrogen estetrol in a multiple-rising-dose study in postmenopausal women. Maturitas. 2016;91:93–100.
   PubMed Web of Science ®Google Scholar
• Gaspard U, Taziaux M, Mawet M, et al. A multicenter, randomized study to select the minimum effective dose of estetrol (E4) in postmenopausal women (E4Relief): part 1. Vasomotor symptoms and overall safety. Menopause. 2020;27(8):848–857.
   PubMed Web of Science ®Google Scholar
• Křepelka P. Estetrol and the possibilities of its clinical use. Česká gynekologie. 2021;86(3):217–221.
   PubMedGoogle Scholar
• Cellai I, Filippi S, Comeglio P, et al. Testosterone positively regulates vagina NO-induced relaxation: an experimental study in rats. J Endocrinol Invest. 2022;45(6):1161–1172.
   PubMed Web of Science ®Google Scholar
• Maseroli E, Vignozzi L. Testosterone and Vaginal Function. Sex Med Rev. 2020;8(3):379–392.
   PubMed Web of Science ®Google Scholar
• Traish AM, Vignozzi L, Simon JA, et al. Role of androgens in female genitourinary tissue structure and function: implications in the genitourinary syndrome of menopause. Sex Med Rev. 2018;6(4):558–571.
   PubMed Web of Science ®Google Scholar
• Fernandes T, Pedro AO, Baccaro LF, et al. Hormonal, metabolic, and endometrial safety of testosterone vaginal cream versus estrogens for the treatment of vulvovaginal atrophy in postmenopausal women: a randomized, placebo-controlled study. Menopause. 2018;25(6):641–647.
   PubMed Web of Science ®Google Scholar
• Davis SR, Robinson PJ, Jane F, et al. Intravaginal testosterone improves sexual satisfaction and vaginal symptoms associated with aromatase inhibitors. J Clin Endocrinol Metab. 2018;103(11):4146–4154.
   PubMed Web of Science ®Google Scholar
• Costa TJ, Ceravolo GS, Echem C, et al. Detrimental effects of testosterone addition to estrogen therapy involve cytochrome P-450-induced 20-HETE synthesis in aorta of ovariectomized Spontaneously Hypertensive Rat (SHR), a Model of postmenopausal hypertension. Front Physiol. 2018;9:490.
   PubMedGoogle Scholar
• Bell RJ, Rizvi F, Islam RM, et al. A systematic review of intravaginal testosterone for the treatment of vulvovaginal atrophy. Menopause. 2018;25(6):704–709.
   PubMed Web of Science ®Google Scholar
• Holton M, Thorne C, Goldstein AT. An overview of dehydroepiandrosterone (EM-760) as a treatment option for genitourinary syndrome of menopause. Expert Opin Pharmacother. 2020;21(4):409–415.
   PubMed Web of Science ®Google Scholar
• Stute P, Bertschy S, Birkhaeuser M, et al. Swiss consensus on the role of DHEA in the management of genitourinary syndrome of menopause. Climacteric. 2022;25(3):246–256.
   PubMedGoogle Scholar
• Johnston S, Bouchard C, Fortier M, et al. Guideline No. 422b: menopause and genitourinary health. J Obstet Gynaecol Can. 2021;43(11):1301–7.e1.
   PubMedGoogle Scholar
• Hocké C, Diaz M, Bernard V, et al. Genitourinary menopause syndrome. Postmenopausal women management: CNGOF and GEMVi clinical practice guidelines. Gynecologie, Obstetrique, Fertilite & Senologie. 2021;49(5):394–413.
   PubMed Web of Science ®Google Scholar
• Pięta W, Smolarczyk R. Vaginal dehydroepiandrosterone compared to other methods of treating vaginal and vulvar atrophy associated with menopause. Prz Menopauzalny. 2020;19(4):667–675.
   Google Scholar
• Johnston S, Bouchard C, Fortier M. Guideline No. 422b: menopause and Genitourinary Health. Journal of Obstetrics and Gynaecology Canada. 2020;27(9):848–857.
   Google Scholar
• Labrie F, Martel C. A low dose (6.5 mg) of intravaginal DHEA permits a strictly local action while maintaining all serum estrogens or androgens as well as their metabolites within normal values. Hormone Molecular Biology and Clinical Investigation. 2017;29(2):39–60.
   PubMed Web of Science ®Google Scholar
• Labrie F, Archer DF, Koltun W, et al. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause. 2016;23(3):243–256.
   PubMed Web of Science ®Google Scholar
• Archer DF, Labrie F, Montesino M, et al. Comparison of intravaginal 6.5 mg (0.50%) prasterone, 0.3 mg conjugated estrogens and 10 μg estradiol on symptoms of vulvovaginal atrophy. J Steroid Biochem Mol Biol. 2017;174:1–8.
   PubMed Web of Science ®Google Scholar
• Sauer U, Talaulikar V, Davies MC. Efficacy of intravaginal dehydroepiandrosterone (DHEA) for symptomatic women in the peri- or postmenopausal phase. Maturitas. 2018;116:79–82.
   PubMed Web of Science ®Google Scholar
• Heo Y-A. Prasterone: a review in vulvovaginal atrophy. Drugs Aging. 2019;36(8):781–788.
   PubMed Web of Science ®Google Scholar
• Bouchard C, Labrie F, Archer DF, et al. Decreased efficacy of twice-weekly intravaginal dehydroepiandrosterone on vulvovaginal atrophy. Climacteric. 2015;18(4):590–607.
   PubMed Web of Science ®Google Scholar
• Henneicke-von Zepelin -H-H, Williams R, Havemeister W, et al. Klinische Studie zeigt anhaltende Wirkung einer neuen Feuchtigkeitscreme gegen Scheidentrockenheit. Wien Med Wochenschr. 2017;167(7–8):189–195.
   PubMedGoogle Scholar
• Vale F, Rezende C, Raciclan A, et al. Efficacy and safety of a non-hormonal intravaginal moisturizer for the treatment of vaginal dryness in postmenopausal women with sexual dysfunction. Eur J Obstet Gynecol Reprod Biol. 2019;234:92–95.
   PubMed Web of Science ®Google Scholar
• De Seta F, Caruso S, Di Lorenzo G, et al. Efficacy and safety of a new vaginal gel for the treatment of symptoms associated with vulvovaginal atrophy in postmenopausal women: a double-blind randomized placebo-controlled study. Maturitas. 2021;147:34–40.
   PubMedGoogle Scholar
• Chen WY, Abatangelo G. Functions of hyaluronan in wound repair. Wound repair and regeneration: official publication of the Wound Healing Society [and] the European Tissue Repair Society. Wound Repair and Regeneration: Official Publication of the Wound Healing Society [And] the European Tissue Repair Society. 1999;7(2):79–89.
   PubMed Web of Science ®Google Scholar
• Jokar A, Davari T, Asadi N, et al. Comparison of the Hyaluronic Acid Vaginal Cream and Conjugated Estrogen Used in Treatment of Vaginal Atrophy of Menopause Women: a Randomized Controlled Clinical Trial. Int J Community Based Nurs Midwifery. 2016;4(1):69–78.
   PubMedGoogle Scholar
• Carter J, Baser RE, Goldfrank DJ, et al. A single-arm, prospective trial investigating the effectiveness of a non-hormonal vaginal moisturizer containing hyaluronic acid in postmenopausal cancer survivors. Support Care Cancer. 2021;29(1):47–58.
   Google Scholar
• Stute P. Is vaginal hyaluronic acid as effective as vaginal estriol for vaginal dryness relief? Arch Gynecol Obstet. 2013;288(6):71–100.
   Google Scholar
• Serati M, Bogani G, Di Dedda MC, et al. A comparison between vaginal estrogen and vaginal hyaluronic for the treatment of dyspareunia in women using hormonal contraceptive. Eur J Obstet Gynecol Reprod Biol. 2015;191:48–50.
   PubMed Web of Science ®Google Scholar
• Cagnacci A, Barattini DF, Casolati E, et al. Polycarbophil vaginal moisturizing gel versus hyaluronic acid gel in women affected by vaginal dryness in late menopausal transition: a prospective randomized trial. Eur J Obstet Gynecol Reprod Biol. 2022;270:1–8.
   PubMedGoogle Scholar
• Nappi RE, Kotek M, Brešt’anský A, et al. Treatment of vulvo-vaginal atrophy with hyaluronate-based gel: a randomized controlled study. Minerva Obstet Gynecol. 2022;74:480–488.
   Google Scholar
• Costantino D, Guaraldi C. Effectiveness and safety of vaginal suppositories for the treatment of the vaginal atrophy in postmenopausal women: an open, non-controlled clinical trial. Eur Rev Med Pharmacol Sci. 2008;12(6):411–416.
   PubMed Web of Science ®Google Scholar
• Amori P, Di Nardo V, Vitiello G, et al. Primavera: a new therapeutical approach to vulvo-vaginal atrophy. Dermatol Ther. 2018;31(6):e12678.
   PubMedGoogle Scholar
• Nappi RE, Kotek M, Brešt’anský A, et al. Effectiveness of hyaluronate-based pessaries in the treatment of vulvovaginal atrophy in postmenopausal women. Climacteric. 2020;23(5):519–524.
   PubMed Web of Science ®Google Scholar
• Angelucci M, Frascani F, Franceschelli A, et al. Efficacy of intradermal hyaluronic acid plus polynucleotides in vulvovaginal atrophy: a pilot study. Climacteric. 2022;25:490–496.
   PubMedGoogle Scholar
• Garavaglia E, Sala C, Busato M, et al. First Use of Thermal Stabilized Hyaluronic Acid Injection in One-Year Follow-Up Patients with Genitourinary Syndrome. Med Devices (Auckl). 2020;13:399–410.
   PubMedGoogle Scholar
• Berreni N, Salerno J, Chevalier T, et al. Evaluation of the effect of multipoint intra-mucosal vaginal injection of a specific cross-linked hyaluronic acid for vulvovaginal atrophy: a prospective bi-centric pilot study. BMC Womens Health. 2021;21(1):322.
   PubMedGoogle Scholar
• Chiechi LM, Putignano G, Guerra V, et al. The effect of a soy rich diet on the vaginal epithelium in postmenopause: a randomized double blind trial. Maturitas. 2003;45(4):241–246.
   PubMedGoogle Scholar
• Grant MD, Marbella A, Wang AT, et al. AHRQ comparative effectiveness reviews. Menopausal Symptoms: Comparative Effectiveness of Therapies. Rockville (MD): Agency for Healthcare Research and Quality (US); 2015.
   Google Scholar
• Le Donne M, Caruso C, Mancuso A, et al. The effect of vaginally administered genistein in comparison with hyaluronic acid on atrophic epithelium in postmenopause. Arch Gynecol Obstet. 2011;283(6):1319–1323.
   PubMed Web of Science ®Google Scholar
• Lima SMR, Bernardo BFA, Yamada SS, et al. Effects of Glycine max (L.) Merr. soy isoflavone vaginal gel on epithelium morphology and estrogen receptor expression in postmenopausal women: a 12-week, randomized, double-blind, placebo-controlled trial. Maturitas. 2014;78(3):205–211.
   PubMed Web of Science ®Google Scholar
• Dizavandi FR, Ghazanfarpour M, Roozbeh N, et al. An overview of the phytoestrogen effect on vaginal health and dyspareunia in peri- and post-menopausal women. Post Reproductive Health. 2019;25(1):11–20.
   PubMedGoogle Scholar
• Munblit D, Abrol P, Sheth S, et al. Levels of growth factors and Iga in the colostrum of women from burundi and italy. Nutrients. 2018;10(9):9.
   Google Scholar
• Vailati S, Melloni E, Riscassi E, et al. Evaluation of the effects of a new intravaginal gel, containing purified bovine colostrum, on vaginal blood flow and vaginal atrophy in ovariectomized rat. Sex Med. 2013;1(2):35–43.
   PubMed Web of Science ®Google Scholar
• Nappi RE, Cagnacci A, Becorpi AM, et al. Monurelle Biogel ® vaginal gel in the treatment of vaginal dryness in postmenopausal women. Climacteric. 2017;20(5):467–475.
   PubMed Web of Science ®Google Scholar
• Schiavi MC, Di Tucci C, Colagiovanni V, et al. A medical device containing purified bovine colostrum (M onurelle B iogel) in the treatment of vulvovaginal atrophy in postmenopausal women: r etrospective analysis of urinary symptoms, sexual function, and quality of life. LUTS: Lower Urinary Tract Symptoms. 2019;11(2):O11–o5.
   PubMedGoogle Scholar
• Laganà AS, Vitale SG, Stojanovska L, et al. Preliminary results of a single-arm pilot study to assess the safety and efficacy of visnadine, prenylflavonoids and bovine colostrum in postmenopausal sexually active women affected by vulvovaginal atrophy. Maturitas. 2018;109:78–80.
   PubMed Web of Science ®Google Scholar
• Lee A, Lee MR, Lee -H-H, et al. Vitamin D Proliferates Vaginal Epithelium through RhoA Expression in Postmenopausal Atrophic Vagina tissue. Mol Cells. 2017;40(9):677–684.
   PubMed Web of Science ®Google Scholar
• Yildirim B, Kaleli B, Düzcan E, et al. The effects of postmenopausal Vitamin D treatment on vaginal atrophy. Maturitas. 2004;49(4):334–337.
   PubMed Web of Science ®Google Scholar
• Rad P, Tadayon M, Abbaspour M, et al. The effect of vitamin D on vaginal atrophy in postmenopausal women. Iran J Nurs Midwifery Res. 2015;20(2):211–215.
   PubMedGoogle Scholar
• Carranza-Lira S, Amador-Pérez C, Macgregor-Gooch AL, et al. [Changes in maturation index and vaginal dryness in postmenopausal women who use or not calcitriol]. Rev Med Inst Mex Seguro Soc. 2012;50(5):537–540.
   PubMedGoogle Scholar
• Kamronrithisorn T, Manonai J, Vallibhakara SA-O, et al. Effect of vitamin D supplement on vulvovaginal atrophy of the menopause. Nutrients. 2020;12(9):9.
   Google Scholar
• Sarebani Z, Alimoradi Z, Aali E, et al. Investigating the effect of vitamin D vaginal suppository on sexual function among postmenopausal women: study protocol for a randomized controlled trial. BMC Womens Health. 2020;20(1):27.
   PubMedGoogle Scholar
• Giardinelli M. [Effect of alpha-tocopherol in some disorders of the menopause and in atrophy of the vaginal mucosa]. Minerva ginecologica. 1952;4(15):579–587.
   PubMedGoogle Scholar
• Golmakani N, Parnan Emamverdikhan A, Zarifian A, et al. Vitamin E as alternative local treatment in genitourinary syndrome of menopause: a randomized controlled trial. International Urogynecology Journal. 2019;30(5):831–837.
   PubMedGoogle Scholar
• Parnan Emamverdikhan A, Golmakani N, Tabassi SAS, et al. A survey of the therapeutic effects of Vitamin E suppositories on vaginal atrophy in postmenopausal women. Iran J Nurs Midwifery Res. 2016;21(5):475–481.
   PubMedGoogle Scholar
• Keshavarzi Z, Janghorban R, Alipour S, et al. The effect of vitamin D and E vaginal suppositories on tamoxifen-induced vaginal atrophy in women with breast cancer. Support Care Cancer. 2019;27(4):1325–1334.
   PubMedGoogle Scholar
• Hummelen R, Macklaim JM, Bisanz JE, et al. Vaginal microbiome and epithelial gene array in post-menopausal women with moderate to severe dryness. PLoS One. 2011;6(11):e26602.
   PubMed Web of Science ®Google Scholar
• Muhleisen AL, Herbst-Kralovetz MM. Menopause and the vaginal microbiome. Maturitas. 2016;91:42–50.
   PubMed Web of Science ®Google Scholar
• Brotman RM, Shardell MD, Gajer P, et al. Association between the vaginal microbiota, menopause status, and signs of vulvovaginal atrophy. Menopause. 2018;25(11):1321–1330.
   PubMed Web of Science ®Google Scholar
• Mitchell CM, Srinivasan S, Zhan X, et al. Vaginal microbiota and genitourinary menopausal symptoms: a cross-sectional analysis. Menopause. 2017;24(10):1160–1166.
   PubMedGoogle Scholar
• Mueck AO, Ruan X, Prasauskas V, et al. Treatment of vaginal atrophy with estriol and lactobacilli combination: a clinical review. Climacteric. 2018;21(2):140–147.
   PubMed Web of Science ®Google Scholar
• Vieira AT, Castelo PM, Ribeiro DA, et al. Influence of oral and gut microbiota in the health of menopausal women. Front Microbiol. 2017;8:1884.
   PubMed Web of Science ®Google Scholar
• Kuzmenko AV, Kuzmenko VV, Gyaurgiev TA. [Experience of application of hormonal and probiotic therapy in the complex treatment of women in peri- and postmenopausal with chronic recurrent bacterial cystitis in the background of vulvovaginal atrophy]. Urologiia. 2019;3:66–71.
   PubMedGoogle Scholar
• Leiblum S, Bachmann G, Kemmann E, et al. Vaginal atrophy in the postmenopausal woman. The importance of sexual activity and hormones. Jama. 1983;249(16):2195–2198.
   PubMed Web of Science ®Google Scholar
• Waetjen LE, Crawford SL, Chang PY, et al. Factors associated with developing vaginal dryness symptoms in women transitioning through menopause: a longitudinal study. Menopause. 2018;25(10):1094–1104.
   PubMed Web of Science ®Google Scholar
• Waetjen LE, Johnson WO, Xing G, et al. Study of Women’s Health Across the Nation (SWAN). patterns of sexual activity and the development of sexual pain across the menopausal transition. Obstet Gynecol. 2022 Jun 1;139(6):1130–1140.
   PubMedGoogle Scholar
• Pinkerton JV, Bushmakin AG, Komm BS, et al. Relationship between changes in vulvar-vaginal atrophy and changes in sexual functioning. Maturitas. 2017;100:57–63.
   PubMed Web of Science ®Google Scholar
• Menkes S, SidAhmed-Mezi M, Meningaud JP, et al. Microfat and nanofat grafting in genital rejuvenation. Aesthet Surg J. 2021;41(9):1060–1067.
   PubMedGoogle Scholar
• Hersant B, SidAhmed-Mezi M, Belkacemi Y, et al. Efficacy of injecting platelet concentrate combined with hyaluronic acid for the treatment of vulvovaginal atrophy in postmenopausal women with history of breast cancer: a phase 2 pilot study. Menopause. 2018;25(10):1124–1130.
   PubMed Web of Science ®Google Scholar
• Saleh DM, Abdelghani R. Clinical evaluation of autologous platelet rich plasma injection in postmenopausal vulvovaginal atrophy: a pilot study. J Cosmet Dermatol. 2022;21:4269–4275.
   Google Scholar
• Condemi L, Di Giuseppe J, Delli Carpini G, et al. Vaginal natural oxygenation device (VNOD) for concomitant administration of hyaluronic acid and topical hyperbaric oxygen to treat vulvo-vaginal atrophy: a pilot study. Eur Rev Med Pharmacol Sci. 2018;22(23):8480–8486.
   PubMed Web of Science ®Google Scholar
• Salvatore S, Nappi RE, Zerbinati N, et al. A 12-week treatment with fractional CO2 laser for vulvovaginal atrophy: a pilot study. Climacteric. 2014;17(4):363–369.
   PubMed Web of Science ®Google Scholar
• Perino A, Calligaro A, Forlani F, et al. Vulvo-vaginal atrophy: a new treatment modality using thermo-ablative fractional CO2 laser. Maturitas. 2015;80(3):296–301.
   PubMed Web of Science ®Google Scholar
• Salvatore S, Leone Roberti Maggiore U, Athanasiou S, et al. Histological study on the effects of microablative fractional CO2 laser on atrophic vaginal tissue: an ex vivo study. Menopause. 2015;22(8):845–849.
   PubMed Web of Science ®Google Scholar
• Zerbinati N, Serati M, Origoni M, et al. Microscopic and ultrastructural modifications of postmenopausal atrophic vaginal mucosa after fractional carbon dioxide laser treatment. Lasers Med Sci. 2015;30(1):429–436.
   PubMed Web of Science ®Google Scholar
• Athanasiou S, Pitsouni E, Antonopoulou S, et al. The effect of microablative fractional CO2 laser on vaginal flora of postmenopausal women. Climacteric. 2016;19(5):512–518.
   PubMed Web of Science ®Google Scholar
• Alexiades M. Nonsurgical Vaginal Treatment with Lasers and Energy-Based Devices. Adv Cosmetic Surgery. 2020;3(1)143–153.
   Google Scholar
• Alexiades-Armenakas MR, Dover JS, Arndt KA. The spectrum of laser skin resurfacing: nonablative, fractional, and ablative laser resurfacing. J Am Acad Dermatol. 2008;58(5):719–737. quiz 38-40.
   PubMed Web of Science ®Google Scholar
• Li F, Picard-Fortin V, Maheux-Lacroix S, et al. The efficacy of vaginal laser and other energy-based treatments on genital symptoms in postmenopausal women: a systematic review and meta-analysis. J Minim Invasive Gynecol. 2021;28(3):668–683.
   PubMedGoogle Scholar
• Khamis Y, Abdelhakim AM, Labib K, et al. Vaginal CO2 laser therapy versus sham for genitourinary syndrome of menopause management: a systematic review and meta-analysis of randomized controlled trials. Menopause. 2021;28(11):1316–1322.
   PubMed Web of Science ®Google Scholar
• Ruanphoo P, Bunyavejchevin S. Treatment for vaginal atrophy using microablative fractional CO2 laser: a randomized double-blinded sham-controlled trial. Menopause. 2020;27(8):858–863.
   PubMed Web of Science ®Google Scholar
• Salvatore S, Pitsouni E, Grigoriadis T, et al. CO(2) laser and the genitourinary syndrome of menopause: a randomized sham-controlled trial. Climacteric. 2021;24(2):187–193.
   PubMed Web of Science ®Google Scholar
• Cruz VL, Steiner ML, Pompei LM, et al. Randomized, double-blind, placebo-controlled clinical trial for evaluating the efficacy of fractional CO2 laser compared with topical estriol in the treatment of vaginal atrophy in postmenopausal women. Menopause. 2018;25(1):21–28.
   PubMed Web of Science ®Google Scholar
• Quick AM, Zvinovski F, Hudson C, et al. Fractional CO2 laser therapy for genitourinary syndrome of menopause for breast cancer survivors. Support Care Cancer. 2020 Aug;28(8):3669–3677. Epub 2019 Dec 6. PMID: 31811486
   PubMed Web of Science ®Google Scholar
• Paraiso MFR, Ferrando CA, Sokol ER, et al. A randomized clinical trial comparing vaginal laser therapy to vaginal estrogen therapy in women with genitourinary syndrome of menopause: the VeLVET Trial. Menopause. 2020;27(1):50–56.
   PubMed Web of Science ®Google Scholar
• Politano CA, Costa-Paiva L, Aguiar LB, et al. Fractional CO2 laser versus promestriene and lubricant in genitourinary syndrome of menopause: a randomized clinical trial. Menopause. 2019;26(8):833–840.
   PubMed Web of Science ®Google Scholar
• Dutra PFSP, Heinke T, Pinho SC, et al. Comparison of topical fractional CO2 laser and vaginal estrogen for the treatment of genitourinary syndrome in postmenopausal women: a randomized controlled trial. Menopause. 2021 May 17;28(7):756–763. PMID: 34010934.
   PubMed Web of Science ®Google Scholar
• Gordon C, Gonzales S, Krychman ML. Rethinking the techno vagina: a case series of patient complications following vaginal laser treatment for atrophy. Menopause. 2019;26(4):423–427.
   PubMed Web of Science ®Google Scholar
• Donders GG, Larsson PG, Platz-Christensen JJ, et al. Variability in diagnosis of clue cells, lactobacillary grading and white blood cells in vaginal wet smears with conventional bright light and phase contrast microscopy. Eur J Obstet Gynecol Reprod Biol. 2009;145(1):109–112.
   PubMed Web of Science ®Google Scholar
• Donders G, Nderlita M, Vertessen VJ, et al. Long term outcome of surgical treatment of central introital dyspareunia. J Clin Med. 2022;11:8.
   Google Scholar